Form 13-F position report

GALMED PHARMACEUTICALS LTD

Reported by MORGAN STANLEY

GLMD CUSIP M47238122 Manager CIK 0000895421

Reported 0 shares, down 36,213 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q3 2024
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 43 Through Q3 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 293000
2022-03-31 263000
2022-06-30 127000
2022-09-30 59000
2022-12-31 90362
2023-03-31 87110
2023-06-30 37369
2023-06-30 0
2023-09-30 12420
2023-12-31 37523
2024-03-31 5020
2024-06-30 9959
2024-09-30 713
2024-09-30 0
2024-12-31 39971
2025-03-31 10634
2025-06-30 61774
2025-09-30 135
2025-12-31 224
2026-03-31 77
2026-06-30 31
2026-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

22 quarters
Quarterly reported position history for GALMED PHARMACEUTICALS LTD held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 0 -56 (-100.0%) 0 $0 2026-11-13
Q2 2026 Reduced 56 -101 (-64.3%) < 0.01% $31 2026-08-13
Q1 2026 Reduced 157 -141 (-47.3%) < 0.01% $77 2026-05-15
Q4 2025 Added 298 +200 (204.1%) < 0.01% $224 2026-02-13
Q3 2025 Reduced 98 -33,475 (-99.7%) < 0.01% $135 2025-11-14
Q2 2025 Added 33,573 +26,188 (354.6%) < 0.01% $61,774 2025-08-15
Q1 2025 Reduced 7,385 -5,145 (-41.1%) < 0.01% $10,634 2025-05-15
Q4 2024 Added 12,530 +12,426 (11948.1%) < 0.01% $39,971 2025-02-14
Q3 2024 Reduced 0 -36,213 (-100.0%) 0 $0 2024-11-14
Q3 2024 New 104 +104 (0.0%) < 0.01% $713 2024-11-14
Q2 2024 Added 36,213 +21,715 (149.8%) < 0.01% $9,959 2024-08-14
Q1 2024 Reduced 14,498 -67,970 (-82.4%) < 0.01% $5,020 2024-05-15
Q4 2023 Added 82,468 +62,436 (311.7%) < 0.01% $37,523 2024-02-13
Q3 2023 Added 20,032 +7,534 (60.3%) < 0.01% $12,420 2023-11-15
Q2 2023 Reduced 0 -204,245 (-100.0%) 0 $0 2023-08-14
Q2 2023 New 12,498 +12,498 (0.0%) < 0.01% $37,369 2023-08-14
Q1 2023 Added 204,245 +23,521 (13.0%) < 0.01% $87,110 2023-05-15
Q4 2022 Reduced 180,724 -8,896 (-4.7%) < 0.01% $90,362 2023-02-14
Q3 2022 Reduced 189,620 -6,079 (-3.1%) < 0.01% $59,000 2022-11-14
Q2 2022 Added 195,699 +30,399 (18.4%) < 0.01% $127,000 2022-08-15
Q1 2022 Added 165,300 +4,500 (2.8%) < 0.01% $263,000 2022-05-13
Q4 2021 Reduced 160,800 -3,700 (-2.2%) < 0.01% $293,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

13 managers reported GALMED PHARMACEUTICALS LTD for Q3 2024.

Managers reporting GALMED PHARMACEUTICALS LTD in Q3 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
TWO SIGMA SECURITIES LLC Reduced 0 -10,330 0 $0 3 qtrs
UBS Group AG Reduced 0 -280 0 $0 6 qtrs
Allworth Financial LP Reduced 0 -17 0 $0 6 qtrs
ZRC WEALTH MANAGEMENT LLC Reduced 0 -7 0 $0 6 qtrs
WELLS FARGO & COMPANY MN Reduced 0 -204 0 $0 6 qtrs
MORGAN STANLEY This report Reduced 0 -36,213 0 $0 6 qtrs
CONCOURSE FINANCIAL GROUP SECURITIES INC Unchanged 0 0 0 $0 6 qtrs
SUSQUEHANNA INTERNATIONAL GROUP LLP Reduced 0 -11,625 0 $0 2 qtrs
Federation des caisses Desjardins du Quebec Reduced 0 -167 0 $0 6 qtrs
ADVISOR GROUP HOLDINGS INC Reduced 0 -53 0 $0 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2024
Filed
November 14, 2024
Filing type
13F-HR
Position type
SHS NEW

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.